Dementia Risk Reduced 20%: New Discovery Revealed
- This article discusses the potential link between the shingles vaccine and a reduced risk of dementia, particularly in women.
- * Shingles Vaccine & Dementia Risk: Recent studies suggest the shingles vaccine may slow the progression of dementia and reduce mortality associated with the disease.
- In essence, the article highlights a promising potential benefit of the shingles vaccine beyond preventing shingles itself - a possible protective effect against dementia - and provides data...
Summary of the Article: Shingles Vaccine and Potential Dementia Protection
This article discusses the potential link between the shingles vaccine and a reduced risk of dementia, particularly in women. Here’s a breakdown of the key points:
* Shingles Vaccine & Dementia Risk: Recent studies suggest the shingles vaccine may slow the progression of dementia and reduce mortality associated with the disease. This effect appears more pronounced in women, potentially due to immunological differences.
* How it Might Work: Researchers propose two main hypotheses:
* reduced Inflammation: Preventing shingles reactivation could reduce chronic inflammation in the central nervous system, a factor in neurodegenerative diseases.
* Immunomodulation: The vaccine might broadly boost the brain’s defenses against various attacks.
* Current Vaccine in France (Shingrix): As of December 14, 2024, the Shingrix vaccine is reimbursed at 65% by French Health Insurance for people aged 65 and over and immunocompromised individuals aged 18 and over.
* Shingrix is Superior: Shingrix is replacing the older Zostavax vaccine (no longer available in France) due to its higher effectiveness: 79% protection against shingles compared to zostavax’s 46%.
* Vaccination Schedule: Two doses of Shingrix are required, spaced two months apart, costing €188.37 (with 65% covered). It can be administered alongside flu, COVID-19, and pneumococcal vaccines.
* Vital Note: The initial studies were conducted with Zostavax. While Shingrix hasn’t been specifically studied for dementia prevention yet, researchers believe its greater effectiveness against shingles could translate to similar or better brain protection. Further clinical trials are underway to confirm these findings.
In essence, the article highlights a promising potential benefit of the shingles vaccine beyond preventing shingles itself – a possible protective effect against dementia - and provides data about access to the currently recommended vaccine (Shingrix) in France.